Welcome back to Stockhouse
Member Sign In

Email or Username:

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

Get our best content in your email.

You are already a member! Please enter your password to sign in.
Quote  |  Bullboard  |  News  |  Opinion  |  Level II  |  Charts  |  Profile  |  Financials  |  Options  |  Price History  |  Analysts  |  Earnings  |  Insiders

Nuvo Research Inc T.NRI

Sector: Healthcare | Sub-Sector: Drug Manufacturers - Specialty & Generic
Alternate Symbol(s):  NRIFF| NRIFD

Nuvo Research Inc is a specialty pharmaceutical company with manufacturing operations. The Company operates two distinct business units, the Topical Products and Technology (TPT) Group and the Immunology Group.
Price: $5.98 | Change: $-0.02 | %Change: -0.33%
Volume: 3,563 | Day High/Low: 5.99/5.85 | 52 Week High/Low: 10.36/2.57
View modes: 
5 stars

Just in Time is a bad joke for Nuvo

Couple of points before I blend back into the scenery. A couple of posters (Rock) have been critical of longs who voted in the present management and now complain of its incompetence. Nobody voted more
0 stars

RE:RE:RE:RE:RE:RE:RE:Revenue / Cash Flow

Drug supply models for outsourced drugs are moving towards JIT (just in time ) . Larger than needed inventories needlessly tie up working capital and depress turnover rates. Turnover rates are one more
0 stars

RE:RE:Oiljack14 how do you explain your Q2 forecast?

sorry...that last sentence should read: "...but Q2 should NOT shoot the lights out, revenue wise."  rate and reply
0 stars

RE:Oiljack14 how do you explain your Q2 forecast?

To the best of my recollection, Q1 contained a high level of regular Pennsaid sales. Since these sales are lumpy from Q to Q, Q2 might be say $600k lower, if they revert to the mean. Also, it seems more
0 stars

Oiljack14 how do you explain your Q2 forecast?

Looking to the weekly chart from Nuvo presentation, the sales are at 6000 btles in Q2  average compare to 3000 btles in Q1 and your private call state for the same revenu for Q2?  Please more
5 stars

RE:RE:RE:RE:RE:RE:Revenue / Cash Flow

SH is hardly a truth and reconciliation body. Otherwise, we would be posting under our real names. It is factual that Horizon has a master manufacturing services contract, as it manufactures none more
0 stars


Remember too that the company is expecting P2% approval for Russia in 2016 and for sales to bgin there as well next year.  The out-licensing process is making progress as I understand it.  Early more
0 stars

RE:RE:RE:RE:RE:Revenue / Cash Flow

Consultant - Very good points.  If and when you decide to pursue the next phase of your activist agenda please inbox me as I have some ideas for you as well. On to my challenging friend. (i) more
5 stars

RE:RE:RE:Revenue / Cash Flow

Consultant you have my full support in monitoring BOD and CEO.( at least with my 70k shares. Thanks again.  rate and reply
0 stars

RE:RE:RE:RE:Revenue / Cash Flow

Yoiu should clarify your teleconference dates. April 22/15 ? Or was this a private teelconference ? How does one correctly interpret your revenue guidance with $7.6 million US committed by more
5 stars

RE:RE:RE:Revenue / Cash Flow

I do not have a forecast for 2015 G & A as there are too many variables to make the exercise worth while. The biggest variable is executive compensation - as of March 31st there were 781,932 more
5 stars

RE:RE:Revenue / Cash Flow

What is your current estimation for G&A burn rate for 2015? Why not start a more activist investor approach such as contacting a fund or two you might have contact with?  Surely with the support more
0 stars

RE:Revenue / Cash Flow

Interesting... John L is adament that they do not provide guidance so I am very interested in knowing who your friend is and why he has access to this information. Secondly the proported more
5 stars

Revenue / Cash Flow

* teleconference notes from a friend. * company is currently gudiing for 2015 revenues of $16 to $17 mm.  Could maybe see up to $2 share in revenue in 2015 if P2% sales continue their robust growth. more
3 stars

RE:Peaked or stabilized

Its pretty dam good. At 7500 week , annual sales will be above $240 million usd. Those are way above initial estimates of less than $100 million. At this rate in the second half, Nuvo should be more
5 stars

Peaked or stabilized

Bottle sales per week between 7000 and 8000 lately. Not bad but I still have a hunch that it will start upward trend in the fall and winter imo only. Refill is required once a month if patient uses more
3 stars

RE:Q2 had some very good P2 sales numbers

Good numbers of about 7500 Rxs which is the second highest on record. At this time if the year......holidays for physicians , salesmen and patients offset by refill can expect more
0 stars

RE:Inflamax WF10 Study

Attached is the brocuhure which matches up to the WF10 study almost perfectly.  rate and reply
5 stars

Inflamax WF10 Study

It would appear that the Nuvo study with Inflamax is full, which is good news (of course this is assuming that the grass and ragweed study is the WF10 study). more
5 stars

Q2 had some very good P2 sales numbers

* record quarter in revnue for NRI should be in the works baed on all public data. * on a go forward basis the revenue numbers should continue to improve and as previulsy stated I am more than more